ALSO READShilpa Medicare Jadcherla facility completes USFDA audit Shilpa Medicare provides update on USFDA inspection of Jadcherla facility Shilpa Medicare board gives nod to Navya Bio's amalgamation Shilpa Medicare gets approval for Azacitidine - Injection ANDA Shilpa Medicare surges on USFDA nod for Jadcherla unit
At meeting held on 01 December 2016Shilpa Medicare announced that the Board of Directors of the Company at its meeting held on 01 December 2016 approved the raising of funds up to Rs 175 crore by issuing equity shares on preferential basis to TA FII Investors, Mauritius at a price of Rs 570 per share of Re 1 each. The Board also proposed to increase the shareholding limit for FIIs'/ FPI and Registered Foreign Investors with SEBI, to 40% from the existing limit of 30%.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)